Cipla Limited has announced the incorporation of a new wholly owned subsidiary, Cipla Middle East Company, in Saudi Arabia through its UK arm Cipla (EU) Limited. The entity will focus on manufacturing, distribution, and marketing authorisations of pharmaceutical products in the Kingdom, effective 1st March 2026.
Cipla Limited has expanded its global footprint with the incorporation of Cipla Middle East Company in Saudi Arabia. The wholly owned subsidiary, established through Cipla (EU) Limited, UK, marks a strategic move to strengthen the company’s presence in the Middle East pharmaceutical market.
Key Highlights
-
Cipla Middle East Company incorporated on 1st March 2026 in Saudi Arabia
-
Entity established as a wholly owned subsidiary of Cipla (EU) Limited, UK
-
Focus on manufacturing, distribution, and holding marketing authorisations for pharmaceutical products in Saudi Arabia
-
Industry alignment with Cipla’s core business in pharmaceuticals
-
No related party transactions involved; incorporation is a step-down subsidiary
-
100% shareholding and control acquired by Cipla (EU) Limited
-
No immediate turnover or acquisition cost applicable at this stage
This development underscores Cipla’s commitment to expanding its international operations and tapping into the growing healthcare demand in the Middle East region.
Source: Cipla Limited, BSE Limited, National Stock Exchange of India Limited, Société de la Bourse de Luxembourg